CANOPY GROWTH INSIDERS GETTING RID OF THEIR SHARES..... moveing to ACB LOLOLOLOL jk not sure
Updated Friday Jun 28, 2019 01:41 AM EDT
Bruce Linton, CEO, Director and 10% Holder, disposed of 347,736 Common Shares on a direct ownership basis at prices ranging from $51.200 to $51.924 on June 26th, 2019. This represents a $17,965,850 divestment of the company's shares and an account share holdings change of -59.0%.
On the same day, Mark Anthony Nicholas Zekulin, a Senior Officer, disposed of 100,000 Common Shares on a direct ownership basis at a price of $51.773. This represents a $5,177,270 divestment of the company's shares and an account share holdings change of -41.5%.
Timothy Rob Saunders, CFO, disposed of 91,666 Common Shares on a direct ownership basis at prices ranging from $51.339 to $51.535 on June 26th, 2019. This represents a $4,715,822 divestment of the company's shares and an account share holdings change of -100.0%.
David Bigioni, a Senior Officer, disposed of 3,600 Common Shares on a control or direction basis for registered holder Jennifer Elaine Bigioni at a price of $52.100 on June 27th, 2019. This represents a $187,560 divestment of the company's shares and an account share holdings change of -93.5%.
Canopy Growth is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.
Canopy Growth Corp, formerly Tweed Marijuana Inc, is a Canada-based multi-brand cannabis company. The Company, through its subsidiaries Tweed Inc, Bedrocan Canada Inc, Tweed Farms Inc and Mettrum Health Corp is engaged in the business of producing and selling legal marijuana in the Canadian medical market. It is also focusing on producing and selling marijuana in the recreational market in Canada. Its core brands are Tweed and Bedrocan. Tweed is a licensed producer of medical marijuana. Tweed's commercial license covers approximately 168,000 square feet of its Smiths Falls facility and allows Tweed to produce and sell approximately 3,540 kilograms of medical marijuana per year. Tweed's built-out production capacity is over 10 climate controlled indoor growing rooms. Bedrocan is a medical-grade cannabis. Bedrocan's over 52,000 square feet production facility in Toronto, Ontario is licensed, and includes over 30 vegetative and growing rooms, and over three dispensing rooms.
